本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截至本公告披露日，持股 5%以上股东连云港康贝尔医疗器械有限公司（以下简 称"康贝尔"）持有江苏康缘药业股份有限公司（以下简称"公司"）31,870,567 股 无限售流通股股份，占公司总股本比例 5.63%；本次股份解除质押业务办理完成后， 康贝尔剩余累计质押的本公司股份数量为 7,000,000 股，占其持有公司股份的 21.96%，占公司总股本的 1.24%。 证券简称：康缘药业 证券代码：600557 公告编号：2025-032 江苏康缘药业股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 近日，公司接到持股 5%以上股东康贝尔的通知，康贝尔将其所持有的公司部分 股份办理了解除质押，相关手续已办理完毕。具体情况如下： | 股东名称 | 连云港康贝尔医疗器械有限公司 | | | --- | --- | --- | | 本次解除质押股份 | 24,870,000 | 股 | | 占其所持股份比例 | 78.03% | | | 占公司总股本比例 ...

康缘药业公告，全资子公司江苏中新医药有限公司近日收到国家药品监督管理局签发的关于ZX2021注 射液新增用于治疗代谢功能障碍相关脂肪性肝病适应症的《药物临床试验批准通知书》。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.34% on October 23, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Notable gainers included: - Qidi Pharmaceutical (Code: 000590) with a closing price of 12.68, up 9.97% and a trading volume of 261,000 shares, totaling 320 million yuan [1] - Zhendong Pharmaceutical (Code: 300158) closed at 7.32, up 4.27% with a trading volume of 1,012,600 shares, totaling 753 million yuan [1] - Major decliners included: - Zhongsheng Pharmaceutical (Code: 002317) closed at 18.43, down 4.75% with a trading volume of 569,600 shares, totaling 1.056 billion yuan [2] - Darentang (Code: 600329) closed at 43.15, down 3.68% with a trading volume of 75,800 shares, totaling 328 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 897 million yuan from institutional investors, while retail investors contributed a net inflow of 989 million yuan [2] - The table of capital flow indicates that: - Qidi Pharmaceutical had a net inflow of 23.93 million yuan from institutional investors, while retail investors had a net outflow of 25.84 million yuan [3] - Zhendong Pharmaceutical experienced a net inflow of 19.97 million yuan from institutional investors, with retail investors seeing a net outflow of 2.25 million yuan [3]

Core Viewpoint - On October 9, a total of 11 listed companies had their restricted shares unlocked, with a total market value of approximately 24.303 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Guo Xin Health (000503) with 1.6798 million shares from equity incentive restrictions - Kang Yuan Pharmaceutical (600557) with 315,500 shares from equity incentive restrictions - Sen Te Co., Ltd. (603098) with 270,000 shares from equity incentive restrictions - San Ren Xing (605168) with 165,300 shares from equity incentive restrictions - Hai Liang Data (603138) with 5.6629 million shares from equity incentive restrictions - Tian Yi Medical (301097) with 40.6 million shares from extended lock-up period - Ming Li Da (301268) with 19 million shares from extended lock-up period - Heng Yu Xintong (300965) with 3.51045 million shares from extended lock-up period - Pu Yuan Jing Dian (688337) with 11.8 million shares unlocked - Zhong Fu Shen Ying (688295) with 29.8 million shares unlocked - Chang Guang Hua Xin (688048) with 7.007 million shares unlocked [1]

Summary of Key Points Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. announced that its major shareholder, Lianyungang Kangber Medical Equipment Co., Ltd., has pledged part of its shares, which may indicate potential liquidity issues or strategic financial maneuvers [1]. Group 1: Shareholding and Pledge Details - Lianyungang Kangber holds 31,870,567 shares of Jiangsu Kangyuan, representing 5.6293% of the total share capital [1]. - After pledging 7 million shares, Kangber has cumulatively pledged 31.87 million shares, which accounts for 99.9982% of its holdings and 5.6292% of the company's total share capital [1]. Group 2: Pledge Usage - The pledged shares are not being used as collateral for major asset restructuring performance compensation or other guarantees [1].

Group 1 - The core point of the article is that Kangyuan Pharmaceutical announced that its major shareholder, Lianyungang Kangbeier Medical Equipment Co., Ltd., has pledged part of its shares, specifically 7 million shares [2] Group 2 - The announcement was made on the evening of September 26 [2] - The shareholder involved holds more than 5% of the company's shares [2]

Group 1 - The core point of the news is that Kangyuan Pharmaceutical has announced a significant share pledge by its subsidiary, Kangbei Medical Equipment, which has pledged 7 million shares, bringing the total pledged shares to 31,870,567, representing 5.6293% of the company's total equity [1] - As of the announcement date, Kangbei has pledged a total of 31,870,000 shares, which accounts for approximately 100% of its holdings in the company [1] - Kangyuan Pharmaceutical's market capitalization is reported to be 8.5 billion yuan [2]

连云港康贝尔医疗器械有限公司（以下简称"康贝尔"）持有江苏康缘药业 股份有限公司（以下简称"公司"）股票 31,870,567 股，占公司总股本的 5.6293%。 本次质押 700 万股后，康贝尔累计质押公司股份 3,187 万股，占其持股数量比例为 99.9982%，占公司总股本比例为 5.6292%。 证券简称：康缘药业 证券代码：600557 公告编号：2025-031 江苏康缘药业股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司于近日收到持股 5%以上股东康贝尔通知，康贝尔将其持有的本公司部分 股票进行质押，现将相关情况公告如下： 一、本次股份质押基本情况 1、本次股份质押基本情况 | 合计 | | | 尔 | 康贝 | | | 名称 | 股东 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | / | | | | 否 | | | 东 | 控股 ...

Core Insights - Innovation has become the core driving force for the development of companies in the pharmaceutical industry in China, as highlighted by Kangyuan Pharmaceutical's recent semi-annual report for 2025, which shows a revenue of 1.642 billion yuan and a research and development (R&D) investment ratio of 15.02% [1][2] - The company has achieved significant results in innovative R&D, with the approval of a new traditional Chinese medicine product, Yunu Jian granules, and five new drugs entering clinical research, including the world's first peptide inhibitor targeting the CCR8 receptor, KYS2301 gel [1][5] Financial Performance - In the first half of 2025, Kangyuan Pharmaceutical reported a revenue of 1.642 billion yuan, maintaining a high R&D investment ratio of 15.02%, which has shown a steady upward trend over the past three years [2][6] - The R&D team has grown to 782 members, indicating strong talent reserves and investment intensity within the industry [2] R&D Pipeline - The company has a diverse product pipeline with 28 products in preclinical stages, 15 in Phase I, 12 in Phase II, and 8 in Phase III, covering multiple therapeutic areas [2] - Kangyuan Pharmaceutical emphasizes the deep development and value re-engineering of existing products, exploring new indications and upgrading technologies to extend product life cycles [2][6] Strategic Framework - The company has established a unique "industry-university-research-application" integrated R&D system, collaborating closely with top institutions like Nanjing University of Chinese Medicine and the Shanghai Institute of Materia Medica [3] - Kangyuan Pharmaceutical has set up a national key laboratory for the control and intelligent manufacturing of traditional Chinese medicine, addressing key technical challenges in the pharmaceutical process [3] Innovation Achievements - Kangyuan Pharmaceutical leads in the field of traditional Chinese medicine innovation, with 58 new traditional Chinese medicine products, 47 of which are unique varieties [5] - The KYS2301 gel, a global first CCR8 peptide inhibitor, has received clinical trial approval and is intended for the treatment of atopic dermatitis [5] Market Strategy - The company adopts a dual strategy of focusing on traditional Chinese medicine while expanding into chemical and biological drugs, particularly in gynecology, respiratory, and cardiovascular disease areas [6][7] - Kangyuan Pharmaceutical is advancing its internationalization efforts through a dual filing strategy in China and the U.S., marking progress in its global market expansion [6][7] Future Outlook - The years 2025-2026 are expected to be crucial for the company, with key milestones such as the reading of Phase II clinical data for ZX2021 and the potential launch of its first biological drug [7] - The company is also enhancing its smart manufacturing capabilities through digital extraction factories and intelligent formulation workshops to improve cost efficiency and product quality [7]

Core Viewpoint - Innovation has become the core driving force for the development of companies in the pharmaceutical industry, as exemplified by Kangyuan Pharmaceutical's strategic focus on innovation and quality to explore new growth points and protect its existing market position [1][7]. Financial Performance and R&D Investment - In the first half of 2025, Kangyuan Pharmaceutical achieved revenue of 1.642 billion yuan, with R&D investment accounting for 15.02% of revenue, maintaining a high level compared to industry standards [1][2]. - The company has seen a steady increase in R&D investment ratio over the past three years, with a current R&D team of 782 people, indicating strong talent reserves and investment intensity [2]. R&D Pipeline and Strategy - Kangyuan Pharmaceutical has a rich product pipeline, with 28 products in preclinical stages, 15 in Phase I, 12 in Phase II, and 8 in Phase III, covering multiple therapeutic areas [2]. - The company emphasizes deep development and value re-creation of existing products, exploring new indications and technological upgrades to extend product life cycles [2][5]. - The strategic focus is on unmet clinical needs, aiming to develop innovative drugs with significant clinical value and unique advantages [2]. Unique R&D Framework - The company has established a unique "industry-university-research-application" integrated R&D system, collaborating closely with top institutions like Nanjing University of Chinese Medicine and Shanghai Institute of Materia Medica [3]. - Kangyuan Pharmaceutical leads the "National Key Laboratory of Process Control and Intelligent Manufacturing Technology for Traditional Chinese Medicine," addressing key technical challenges in the pharmaceutical process [3]. Innovation Achievements - Kangyuan Pharmaceutical has maintained a leading position in TCM innovation, with 58 new TCM drugs, 47 of which are exclusive varieties [4]. - The approval of the TCM new drug Yunu Jian Granules exemplifies the modernization of ancient classic formulas [4]. - The company has made significant breakthroughs in chemical and biological drugs, with KYS2301 gel being the world's first CCR8 peptide inhibitor approved for clinical trials [4]. Market Strategy and Future Outlook - The company adopts a "one body, two wings" development strategy, focusing on TCM while expanding into chemical and biological drugs, particularly in gynecology, respiratory, and cardiovascular fields [6]. - Kangyuan Pharmaceutical is progressing in internationalization with a dual reporting strategy in China and the U.S., marking new advancements in its international market expansion [6]. - The period of 2025-2026 is expected to be crucial for the company's R&D output, with key milestones anticipated in clinical data and product launches [6]. Strategic Balance - Kangyuan Pharmaceutical's strategy balances innovation and tradition, allowing it to navigate industry policy changes and market competition effectively [7]. - The company's 15.02% R&D investment is viewed as essential ammunition for its long-term strategic "offensive and defensive" approach [7].